Citius Oncology Inc CTOR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
-
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
-
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
-
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
-
Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization
-
Citius Oncology Ships First International Order of LYMPHIR™ to Europe
Trading Information
- Previous Close Price
- $0.73
- Day Range
- $0.70–0.73
- 52-Week Range
- $0.49–4.28
- Bid/Ask
- $0.70 / $0.73
- Shares Outstanding
- 92.98M
- Market Cap
- $67.07M
- Volume/Avg
- 18,238 / 83,769
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 10.67
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 0
- Website
- https://www.citiusonc.com
Valuation
|
Metric
|
CTOR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.87 |
Price/Sales | 10.67 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CTOR
|
|---|---|
Quick Ratio | 0.06 |
Current Ratio | 0.50 |
Interest Coverage | −140.65 |
Quick Ratio
CTOR
Profitability
|
Metric
|
CTOR
|
|---|---|
Return on Assets (Normalized) | −33.45% |
Return on Equity (Normalized) | −80.12% |
Return on Invested Capital (Normalized) | −73.04% |
Return on Assets
CTOR
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|P>^<!W> | LOCK|!X?@L | $69B | |||
| Haleon PLC ADR
HLN
| LOCK|x$SZn%& | LOCK|vRb | $43B | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| LOCK|rpB!ZLK | LOCK|%>WV | $38B | |||
| Zoetis Inc Class A
ZTS
| LOCK|G#xC!mC | LOCK|W< | $31B | |||
| Viatris Inc
VTRS
| LOCK|hQ@WZ# | LOCK|L?n | $19B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|Q% | LOCK|$> | $12B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|Rn<#%>$ | LOCK|?b> | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|PfZps% | LOCK|<@? | $8B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|z&h?#?T | LOCK|HfHR | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|L!%qSYY | LOCK|d!# | $1B |
United States